Literature DB >> 15565522

[Analysis of expression of estrogen (ER) and progesterone receptors (PR) in brain glial tumors and its correlation with expression of p53 protein and proliferating cell nuclear antigen (PCNA)].

Władysław Berny1, Artur Weiser, Włodzimierz Jarmundowicz, Alicja Markowska-Woyciechowska, Rafał Załuski, Wojciech Zub.   

Abstract

BACKGROUND AND
PURPOSE: All the types of the glial cells contain estrogen (ER) and progesterone receptors (PR) but their occurrence in glial tumors of the brain is still controversial. The aim of this research was the clinical analysis of ER and PR expression in correlation with histological malignancy and expression of p53 and PCNA.
MATERIAL AND METHODS: The investigation was carried out on a group of 56 patients operated on at the Neurosurgical Department of Wroclaw Medical University. The percentage of tumors containing ER and PR was assessed and mean receptor expressions were compared. Classical histological tests, immunohistochemical tests for ER, PR, p53 and PCNA with monoclonal antibodies (DACO) were performed for every specimen of tumor tissue.
RESULTS: ER occurred in 24 cases (42.9%), PR in 10 cases (17.9%). 49% of highly malignant gliomas (WHO III and IV) were ER positive, whereas 29% of tumors grade I and II were ER positive. Frequencies of PR positive tumors were similar in both groups. Mean PR expression in p53 positive group was 8% and in p53 negative group 1.5% (p=0.017). Mean ER expression in PCNA positive group was 7.4%, whereas in PCNA negative group 2.7% (p<0.01).
CONCLUSIONS: Frequency of ER occurrence is higher in highly malignant tumors. ER expression is correlated with proliferative activity (PCNA). PR expression is positively correlated with intensity of mutant p53 protein.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15565522

Source DB:  PubMed          Journal:  Neurol Neurochir Pol        ISSN: 0028-3843            Impact factor:   1.621


  4 in total

1.  Aromatase and estrogen receptor alpha mRNA expression as prognostic biomarkers in patients with astrocytomas.

Authors:  J M Dueñas Jiménez; A Candanedo Arellano; A Santerre; S Orozco Suárez; H Sandoval Sánchez; I Feria Romero; R López-Elizalde; M Alonso Venegas; B Netel; B de la Torre Valdovinos; S H Dueñas Jiménez
Journal:  J Neurooncol       Date:  2014-07-09       Impact factor: 4.130

2.  Selective transcriptional regulation of aromatase gene by vitamin D, dexamethasone, and mifepristone in human glioma cells.

Authors:  Josue G Yague; Luis M Garcia-Segura; Iñigo Azcoitia
Journal:  Endocrine       Date:  2008-12-31       Impact factor: 3.633

Review 3.  Expression of estrogen and progesterone receptors in astrocytomas: a literature review.

Authors:  Cléciton Braga Tavares; Francisca das Chagas Sheyla Almeida Gomes-Braga; Danylo Rafhael Costa-Silva; Carla Solange Escórcio-Dourado; Umbelina Soares Borges; Airton Mendes Conde-Junior; Maria da Conceição Barros-Oliveira; Emerson Brandão Sousa; Lorena da Rocha Barros; Luana Mota Martins; Gil Facina; Benedito Borges da-Silva
Journal:  Clinics (Sao Paulo)       Date:  2016-08       Impact factor: 2.365

4.  Androgen Receptor, Although Not a Specific Marker For, Is a Novel Target to Suppress Glioma Stem Cells as a Therapeutic Strategy for Glioblastoma.

Authors:  Nan Zhao; Fei Wang; Shaheen Ahmed; Kan Liu; Chi Zhang; Sahara J Cathcart; Dominick J DiMaio; Michael Punsoni; Bingjie Guan; Ping Zhou; Shuo Wang; Surinder K Batra; Tatiana Bronich; Tom K Hei; Chi Lin; Chi Zhang
Journal:  Front Oncol       Date:  2021-05-21       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.